Tiziana Life Sciences

Tiziana Life Sciences is a publicly traded biotechnology company. Our mission is to design and deliver next-generation immunotherapies for neurodegenerative, gastrointestinal, and pulmonary diseases. Our lead immunotherapy candidate, Foralumab (TZLS-401), is in development for Crohn’s disease, multiple sclerosis, and autoimmune conditions. We believe that Foralumab is the only fully human anti-CD3 monoclonal antibody currently in clinical development, with the potential to minimize adverse immune responses in patients.